§ Funding Round
ILiAD Biotechnologies raised $115M Series D venture round, led by RA Capital Management.
ILiAD Biotechnologies, a clinical-stage biotechnology company based in New York, New York, United States, North America, has successfully closed an oversubscribed Series B funding round, raising $115 million. The company is dedicated to the prevention and treatment of diseases caused by Bordetella Pertussis, the bacterium responsible for whooping cough, with the aim of addressing the significant global burden of this respiratory illness.
| Investor | Firm Type | Partner |
|---|---|---|
| Organization | — | |
| Organization | — | |
Janus Henderson Investors | — | — |
| Organization | — | |
BNP Capital | — | — |
This company has completed 5 funding rounds. Current round is highlighted.
Total Raised
$286.6M
Top Valuation
-
ILiAD Biotechnologies is a clinical-stage biotechnology company focused on the prevention and treatment of diseases caused by Bordetella Pertussis, the bacterium responsible for whooping cough.
ILiAD Biotechnologies successfully closed an oversubscribed Series B funding round, raising $115 million to advance its pertussis vaccine candidate, BPZE1.
BPZE1 is ILiAD Biotechnologies' next-generation live attenuated intranasal pertussis vaccine candidate, designed to provide durable and comprehensive immunity against Bordetella Pertussis infection, disease, and transmission.
ILiAD Biotechnologies expects to initiate a pivotal human challenge trial for BPZE1 in 2026, with initial data anticipated in 2027.
[{'heading': 'SIGNIFICANCE OF THE $115M SERIES B FUNDING', 'content': "The substantial $115 million Series B funding round, led by RA Capital Management and including new investors such as Janus Henderson Investors and BNP Paribas Asset Management Alts, marks a pivotal moment for ILiAD Biotechnologies. This oversubscribed financing underscores strong investor confidence in the company's innovative approach to combating pertussis and its vaccine candidate, BPZE1. The capital infusion will accelerate the crucial development stages of their live attenuated intranasal pertussis vaccine."}, {'heading': 'ADVANCING THE BPZE1 VACCINE CANDIDATE', 'content': "A significant portion of the Series B proceeds will be allocated to advancing BPZE1, ILiAD's next-generation pertussis vaccine candidate. BPZE1 is designed to provide durable and comprehensive immunity against Bordetella Pertussis infection, disease, and transmission. This live attenuated intranasal vaccine represents a novel strategy to address the limitations of existing pertussis vaccines and offer improved protection against this highly contagious respiratory infection."}, {'heading': 'ADDRESSING THE GLOBAL PERTUSSIS BURDEN', 'content': "Pertussis, commonly known as whooping cough, continues to be a global health challenge, affecting millions annually and causing substantial mortality, particularly in young children. ILiAD Biotechnologies' mission is to mitigate this ongoing burden through the development of more effective preventative measures. The successful funding round empowers the company to make significant strides in bringing BPZE1 closer to patients, thereby offering a potentially transformative solution to this critical public health issue."}, {'heading': 'UPCOMING MILESTONES: PIVOTAL HUMAN CHALLENGE TRIAL', 'content': "Looking ahead, ILiAD Biotechnologies is poised to initiate a pivotal human challenge trial for BPZE1 in 2026. This critical clinical milestone will further evaluate the vaccine's efficacy and safety, with initial data anticipated in 2027. The successful completion of this trial will be a key step toward regulatory approval and ultimately making BPZE1 available to a wider population in need of enhanced pertussis protection."}]
